SGLT2 Inhibitors and Cardiovascular Outcomes in Patients With Fabry Disease: Observations From a Federated Research Network
Diabetes, Obesity & Metabolism
The paper
Serio L, Rossi M, Askarinejad A et al.
Diabetes, Obesity & Metabolism · 8 Sep 2026
More on SGLT2 inhibitors
SGLT2 inhibitors raise genital but not urinary infection risk
Clinical Pharmacology and Therapeutics · 4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Diabetes & Vascular Disease Research · 4 Oct 2026
Low-carb telemedicine links to fewer cardiovascular events
Cardiology and Therapy · 4 Oct 2026
Early physical therapy links to lower mortality in heart failure
Journal of Clinical Medicine · 4 Oct 2026